AKT1 and prostate carcinoma: For instance, it reverses docetaxel resistance in prostate cancer through the androgen receptor and PI3K/Akt signaling pathway (Lu et al. 2020), and reverses multi‐drug resistance in hepatocellular carcinoma cells through the FZD7/β‐catenin pathway (Chen et al. 2018).